Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EC holds patent policy hearing to collect stakeholders' views:

This article was originally published in Clinica

Executive Summary

A total of 360 people have already registered for the European Commission's public hearing, in Brussels July 12, on the future of EU patent policy. This is the second step of the public consultation launched in January this year, which is focusing on the structure of the patent system in Europe rather than issues of substantive patent law. There had been some 2,000 replies to the written consultation, and the intention is for these to be published. The Commission will prepare a report summarising the outcome of both the written submissions and the July hearing, and post this on its website. It will then decide on the operational consequences. For further details, see: http://europa.eu.int/comm/internal-market/indprop/patent/ consultation-en.htm

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT052089

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel